Nierenzellkarzinom

  • A. D. H. Geboers
  • F. M. J. Debruyne

Zusammenfassung

Histologisch wird nachfolgendem Wachstumsverhalten unterschieden: trabekulär, alveolär, tubulär und solide.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Silverberg E, Boring CC, Squires (1990) Cancer statistics. CA 40: 9–26CrossRefGoogle Scholar
  2. 2.
    Paganini-Hill A, Ross RK, Henderson BE (1983) Epidemiology of kidney cancer. In: Skinner DG (ed) Urological cancer. Grune & Stratton, New York, pp 383–407Google Scholar
  3. 3.
    Bears OH, Henson DE, Huffer RVP, Meyers MH (1988) Manual for staging of cancer. Third edition. Lippincott, PhiladelphiaGoogle Scholar
  4. 4.
    Krown SE, Einzig Al, Abramson JD et al. (1983) Treatment of advanced renal cell cancer ( RCC) with recombinant leucocyte A interferon (rIFN-aA ). Proc Am Soc Clin Oncol 2: 58Google Scholar
  5. 5.
    Einzig Al, Krown SE, Oettgen HF (1984) Recombinant leucocyte-a interferon WEN-a) in renal cell cancer. Proc Am Soc Clin Oncol 4: 54Google Scholar
  6. 6.
    Krown SE (1985) Therapeutic options in renal-cell carcinoma. Semin Oncol 12: 13–17PubMedGoogle Scholar
  7. 7.
    Quesada JR, Rios A, Swanson D et al. (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522–1528PubMedGoogle Scholar
  8. 8.
    Buzaid AC, Robertone A, Kisala C et al. (1987) Phase II study of interferon alpha-2a, recombinant ( ROFERON A) in metastatic renal cell carcinoma. J Clin Oncol 5: 1083–1089Google Scholar
  9. 9.
    Figlin RA, de Kernion JB, Mukamel E et al. (1988) Recombinant interferon alpha-2a in metastatic renal cell carcinoma. Assessment of antitumor activity and anti-interferon-antibody formation. J Clin Oncol 6: 1604–1610Google Scholar
  10. 10.
    Schnall SF, Davis C, Kirkwood JM et al. (1986) Treatment of metastatic renal cell carcinoma (RCC) with intramuscular (IM) recombinant interferon alpha A ( IFN, Hoffmann-La Roche) Proc Am Soc Clin Oncol 5: 227Google Scholar
  11. 11.
    Fossa SD (1988) Is interferon with or without Vinblastine the “treatment of choice” in metastatic renal cell carcinoma? The Norwegian Radium Hospital’s experience 1983–1986. Semin Surg Oncol 4: 178–183PubMedCrossRefGoogle Scholar
  12. 12.
    Umeda T, Niijima N (1986) Phase II study on alpha interferon on renal cell carcinoma: Summary of three collaborative trials. Cancer 58: 1231–1235Google Scholar
  13. 13.
    Muss HB, Costanzi JJ, Leavitt R et al. (1987) Recombinant interferon alpha in renal cell carcinoma: a randomised trial of two routes of administration. J Clin Oncol 5: 286–291PubMedGoogle Scholar
  14. 14.
    Foon K, Doroshow J, Bonnern E et al. (1988) A prospective randomised trial of a2b-interferon/g-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Resp Mod 7: 540–545Google Scholar
  15. 15.
    Porzsolt F, Messerer D, Hautmann R et al. (1988) Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. J Cancer Res Clin Oncol 114: 95–100PubMedCrossRefGoogle Scholar
  16. 16.
    Otto U, Bauer HW, Jager N (1987) Alpha-2 recombinant interferon treatment of metastatic renal cell carcinoma. International symposium on the status of treatment of metastatic renal cell carcinoma, IUCC. Vienna Austria, 13–14 March 1987. AbstractGoogle Scholar
  17. 17.
    Takaku F, Kumamoto Y, Koiso K et al. (1987) Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Cancer 60: 929–933CrossRefGoogle Scholar
  18. 18.
    Quesada JR, Kurzrock P, Sherwin A et al. (1987) Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Resp Mod 6: 20–27Google Scholar
  19. 19.
    Gamick MB, Reich SD, Maxwell B et al. (1988) Phase I/II trial of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 139: 251–255Google Scholar
  20. 20.
    Kuebler JP, Goodmann PJ, Brown TD et al. (1990) Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma, a South West Oncology Group Study. Invest New Drugs 8: 307–309PubMedCrossRefGoogle Scholar
  21. 21.
    Bruntsch U, de Mulder PHM, ten Bokkel Huinink WW et al. (1990) Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma. J Biol Resp Mod 9: 335338Google Scholar
  22. 22.
    Rinehart JJ, Malspeis L, Young D et al. (1986) Phase I/II trial of human recombinant ß-interferon serine in patients with renal cell carcinoma. Cancer Res 46: 5364–5367PubMedGoogle Scholar
  23. 23.
    Rinehart JJ, Young D, Laforge J et al. (1987) Phase I/II trial of interferon-ß-serine in patients with renal cell carcinoma, Immunological and biological effects. Cancer Res 47: 2481–2485Google Scholar
  24. 24.
    Quesada JR, Evans L, Saks SR et al. (1988) Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J Biol Resp Mod 7: 234239Google Scholar
  25. 25.
    Geboers ADH, de Mulder PHM, Debruyne FMJ et al. (1988) alpha and gamma interferon in the treatment of advanced renal cell carcinoma. Sem Surg Oncol 4: 191–194Google Scholar
  26. 26.
    Kinney P, Triozzi P, Young D et al. (1990) Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma. J Clin Oncol 5: 881–885Google Scholar
  27. 27.
    Ernstoff MS, Nair S, Bahnson RR et al. (1990) A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 8: 1637–1649PubMedGoogle Scholar
  28. 28.
    Quesada JR, Swanson DA, Gutterman GU (1985) Phase II study of interferon alpha in metastatic renal cell carcinoma: a progress report. J Clin Oncol 3: 1086–1092PubMedGoogle Scholar
  29. 29.
    Quesada JR Swanson DA, Trindade A et al. (1983) Renal cell carcinoma: antitumor effects of leucocyte interferon. Cancer Res 43: 940–947PubMedGoogle Scholar
  30. 30.
    DeKernion B, Sarna G, Figlin R et al. (1983) The treatment of renal cell carcinoma with human leucocyte alpha-interferon. J Urol 130: 1063–1066PubMedGoogle Scholar
  31. 31.
    Kirkwood JM, Harris JE, Vera R et al. (1985) A randomised study of low and high doses of leucocyte a-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial. Cancer Res 45: 863–871Google Scholar
  32. 32.
    Neidhart JA, Gagen MM, Young D et al. (1984) Interferon-a therapy of renal cancer. Cancer Res 44: 4140–4143PubMedGoogle Scholar
  33. 33.
    Neidhart JA, Gagen M, Kirsner et al. (1984) Therapy of renal cancer with low (LD), intermediate (ID) and high (HD) dose regimens of human lymphoblastoid interferon (HBLI; Wellferon ). Proc An Soc Clin Oncol 1984: 60Google Scholar
  34. 34.
    Trump DL, Elson PJ, Borden EC et al. (1987) High dose lymphoblastoid interferon in advanced renal cell carcinoma: An Eastern Cooperative Oncology Group Study. Cancer Treat Rep 71: 165–169Google Scholar
  35. 35.
    Vugrin D, Hood L, Taylor W et al. (1985) A phase II study of human lymphoblastoid interferon in renal cell carcinoma. Cancer Treat Rep 69: 817–820PubMedGoogle Scholar
  36. 36.
    Eisenhauwer EA, Silver HK, Venner PM et al. (1987) Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. Br J Cancer 55: 541542Google Scholar
  37. 37.
    Fujita T, Haruyosi A, Naide Y et al. (1988) Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma. J Urol 139: 256–258PubMedGoogle Scholar
  38. 38.
    Levens W, Rübben H, Ingenhag W (1989) Long-term Interferon treatment in metastatic renal cell carcinoma. Eur Urol 16: 378–381PubMedGoogle Scholar
  39. 39.
    Otto U, Conrad S, Schneider AW et al. (1988) Recombinant Interferon gamma in the treatment of metastatic renal cell carcinoma. Arzneim-Forsch/Drug Res 38 (11): 1658–1660Google Scholar
  40. 40.
    Figlin RA, deKernion JB, Maldazys J et al. (1985) Treatment of renal cell carcinoma with a(human leucocyte) interferon and vinblastine in combination: a phase I—II trial. Cancer Treat Rep 69: 263–267PubMedGoogle Scholar
  41. 41.
    Fossa SD, DeGarris ST, Heier MS et al. (1986) Recombinant interferon alpha-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 57: 1700–1704PubMedCrossRefGoogle Scholar
  42. 42.
    Cetto GL, Franceschi T, Turina G et al. (1988) Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses. Sem Surg Oncol 4: 184–190CrossRefGoogle Scholar
  43. 43.
    Kellokumpu-Lehtinen P, Nordman E (1990) Recombinant interferon-a2a and vinblastine in advanced renal cell cancer: a clinical Phase I—II study. J Biol Resp Mod 9: 439–444Google Scholar
  44. 44.
    Bergerat J-P, Herbrecht R, Dufour P (1988) Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. Cancer 62: 2320–2324PubMedCrossRefGoogle Scholar
  45. 45.
    Sertoli MR, Brunetti I Ardizzoni A et al. (1989) Recombinant a-2a Interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. J Clin Oncol 12: 43–45CrossRefGoogle Scholar
  46. 46.
    Trump DL, Ravdin PM, Borden EC et al. (1990) Interferon-or-n1 and continuous infusion vinblastine of advanced renal cell carcinoma. J Biol Resp Mod 9: 108–111Google Scholar
  47. 47.
    Schornagel JH, Verwey J, ten Bokkel Huinink WW et al. (1989) Phase lI study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. J Urol 142: 253–256PubMedGoogle Scholar
  48. 48.
    Bloom HJG (1971) Medroxyprogesteron acetate in the treatment of metastatic renal cancer. Br J Caner 25: 250–265CrossRefGoogle Scholar
  49. 49.
    Hrushesky WJ, Murphy GP (1977) Current status of the therapy of advanced renal carcinoma. J Surg Oncol 9: 277–288PubMedCrossRefGoogle Scholar
  50. 50.
    Jakse G, Müller-Holzner E (1988) Hormone receptors in renal cancer. Sem Surg Oncol 4: 161–164CrossRefGoogle Scholar
  51. 51.
    Harris DT (1983) Hormonal therapy and chemotherapy of renal cell carcinoma. Sem Oncol 10: 422–430Google Scholar
  52. 52.
    Oliver IN, Leavitt RD (1984) Chemotherapy and immunotherapy in disseminated renal cancer. In: Javadpour N (ed) Cancer of the kidney. Thieme Stratton, New York, pp 109120Google Scholar
  53. 53.
    Bell DR, Aroney RS, Fisher RJ, Levi JA (1984) High dose methotrexate with leucovorin rescue, vinblastine and bleomycin with or without tamoxifen in metastatic renal cell carcinoma. Cancer Treat Rep 68: 587–590PubMedGoogle Scholar
  54. 54.
    Fowler JE (1987) Nephrectomy in renal cell carcinoma. Urol Clin N Am 14: 749–756Google Scholar
  55. 55.
    Brady LW (1983) Carcinoma of the kidney — Role of radiotherapy. Semin Oncol 10: 417–421PubMedGoogle Scholar
  56. 56.
    Maor MH, Frias AE, Oswald MJ (1988) Palliative radiotherapy for brain metastases in renal cell carcinoma. Cancer 62: 1912–1917PubMedCrossRefGoogle Scholar
  57. 57.
    Fairlamb DJ (1981) Spontaneous regression of metastases of renal cancer. A report of two cases including the first recorded regression following irradiation of a dominant metastases and review of the world literature. Cancer 47: 2101–2106CrossRefGoogle Scholar
  58. 58.
    Buzaid AC, Todd MB (1989) Therapeutic options in renal cell carcinoma. Semin Oncol 16: 12–19PubMedGoogle Scholar
  59. 59.
    Jones GJ, Loretta MI (1986) Safety and tolerance of recombinant interferon alfa-2a ( Roteron-A) in cancer patients. Cancer 57: 1709–1715Google Scholar
  60. 60.
    Dekernion. Oral presentation AUA 1991Google Scholar
  61. 61.
    Mulder de PHM, Debruyne FMJ, Fransen MPH, Geboers ADH, Strijk S, Reintjes A, Doesburg WH, Damsma 0 (1990) Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma. Cancer Immunol Immunother 31: 321–324Google Scholar
  62. 62.
    Czarniecki CW, Cristopher WF, Powers DB, Estell DA (1984) Synergistic antiviral and anti-proliferative activities of Escherichia Coli-derived human alpha, beta and gamma interferons. J Virol 49: 490PubMedGoogle Scholar
  63. 63.
    Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K, Steis RG (1988) The determination of an immunologically active dose of interferon gamma in patients with melanoma. J Clin Oncol 6: 434PubMedGoogle Scholar
  64. 64.
    Bonnem EM (1987) Alpha interferon: combination with other antineoplastic modalities. Semin Oncol 14 (2): 48–60PubMedGoogle Scholar
  65. 65.
    Muss HB, Welander C, Caponera M et al. (1985) Interferon and doxorubicin in renal cell carcinoma. Cancer Treat Rep 69 (6): 721–722PubMedGoogle Scholar
  66. 66.
    Creagan ET, Buckner JC, Hahn RG, Richardson RR, Scheid DJ, Kovach JS (1988) An evaluation of recombinant leucocyte A interferon with aspirin in patients with metastatic renal cell cancer. Cancer 61: 1787–1791PubMedCrossRefGoogle Scholar
  67. 67.
    Hubbell HR, Craft JA, Leibowitz PJ, Gillespie DH (1987) Synergistic antiproliferative effect of recombinant alpha interferon with recombinant gamma interferon. J Biol Resp Mod 6: 141–153Google Scholar
  68. 68.
    Mulder de PHM, Debruyne FMJ, van Oosterom A, Bouffioux C, Vermeylen K, Sylvester R (1991) EORTC randomised phase II study of recombinant interferon alpha and gamma in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 166Google Scholar
  69. 69.
    Wadler S, Einzig Al, Dutcher JP et al. (1988) Phase II trial of recombinant Alpha 2b-interferon and low dose cyclophosphamide in advanced melanoma and renal cell carcinoma. J Clin Oncol 11: 55–59CrossRefGoogle Scholar
  70. 70.
    Mulder de PHM, Debruyne FMJ, Rikken G et al. (1989) Recombinant (r) tumor necrosis factor alpha (TNF-alpha) plus interferon-gamma (IFN-gamma) in the treatment of advanced renal cell carcinoma ( RCC ). Proc Am Soc Clin Oncol 8: 144Google Scholar
  71. 71.
    Rosenberg SA, Lotze MT, Jang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry SM, Steinberg S, White DE (1989) Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863–1874PubMedGoogle Scholar
  72. 72.
    Negrier S, Philip T, Stoter G et al. (1990) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicenter study. Eur J Cancer Clin Oncol 25: 21–28Google Scholar
  73. 73.
    Rosenberg SA, Lotze MT, Yang JC et al. (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485PubMedCrossRefGoogle Scholar
  74. 74.
    Sosman JA, Kohler PC, Hank. A, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80: 60–63Google Scholar
  75. 75.
    Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver, Bander NH, Rubin AL, Stenzel KH (1989) A phase II clinical trial of adoptive immunotherapy for advanced renal carcinoma using mitogen-activated autologous leucocytes and continuous infusion interleukin-2. J Clin Oncol 7 (12): 1885–1891PubMedGoogle Scholar
  76. 76.
    Fisher RI, Coltman CA, Doroshow JA (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells. Ann Int Med: 518–523Google Scholar
  77. 77.
    Bukowski RM, Goodman P, Crawford D, Sergi JS, Redman BG, Whitehead RP (1990) Phase II trial of high dose intermittent interleukin-2 in metastatic renal cell carcinoma: A South West Oncology Group study. J Natl Cancer Inst 82: 143–146Google Scholar
  78. 78.
    West WH (1989) Continuous infusion recombinant interleukin-2 (rll-2) and adoptive cellular therapy of renal cell carcinoma and other malignancies. Cancer Treat Rev 16: 83–89PubMedCrossRefGoogle Scholar
  79. 79.
    West WH, Tauer KW, Yanelle JR et al. (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905PubMedCrossRefGoogle Scholar
  80. 80.
    Parkinson DR, Fisher RI, Rayner AA et al. (1990) Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8: 1630–1636PubMedGoogle Scholar
  81. 81.
    Krigel RL, Radavic Shaller KA, Rudolph AR, Konrad M, Bradley ED, Comis RL (1990) Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta interferon. J Clin Oncol 8: 460–467PubMedGoogle Scholar
  82. 82.
    Atzpodien J, Poliwoda H, Kirchner H (1991) Alpha interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol 19 (7): 108–112Google Scholar
  83. 83.
    Negrier S, Ravaud A, Bui BN et al. (1991) Subcutaneous interleukin-2(II-2) and interferon alpha (IFN) in metastatic renal cell cancer (MRCC): a double institution study on 37 patients. Eur J Cancer (Suppl 2 ) 223: 1365Google Scholar
  84. 84.
    Stoter G, Goey SH, Eggermont AMM et al. (1990) Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek. Biotherapy 2: 261–265Google Scholar
  85. 85.
    Fossa SD, Gunderson R, Moe B (1990) Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Cancer 65: 2451–2454PubMedCrossRefGoogle Scholar
  86. 86.
    Giuliani L, Giberti C, Martorana G, Rovida S (1990) Radical extensive surgery for renal cell carcinoma: long term survival and prognostic factors. J Urol 143: 468–474PubMedGoogle Scholar
  87. 87.
    Herrlinger A, Schrott KM, Schott G, Sigel A (1991) What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma? J Urol 146: 1224–1227PubMedGoogle Scholar
  88. 88.
    Geboers ADH, Debruyne FMJ (1992) Limitations of surgical curability in renal cell carcinoma. EORTC Genitourinary Group Monograph 11: Recent progress. In: Schröder FH (ed) Bladder and kidney cancer. Wiley-Liss Inc, pp 175–186Google Scholar
  89. 89.
    Geboers ADH, Jansen EPM, Bauland CG, Oosterhof GON, Debruyne FMD (1992) Prognostic factors for the treatment of metastatic renal cell carcinoma with biological response modifiers. Genoa, July 1992, abstractGoogle Scholar
  90. 90.
    TNM classification of malignant tumors. Fourth edition, 2nd revision, 1992Google Scholar
  91. 91.
    Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • A. D. H. Geboers
  • F. M. J. Debruyne

There are no affiliations available

Personalised recommendations